PMID- 7585649
OWN - NLM
STAT- MEDLINE
DCOM- 19951214
LR  - 20181130
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 55
IP  - 23
DP  - 1995 Dec 1
TI  - Methylcholanthrene-induced mouse sarcomas express individually distinct major 
      histocompatibility complex class I-associated peptides recognized by specific 
      CD8+ T-cell lines.
PG  - 5648-55
AB  - Mouse sarcomas induced by methylcholanthrene (MC) are immunologically distinct 
      even if they are induced in the same strain of mice. T-cell lines were derived 
      from mice immunized against a series of syngeneic MC sarcomas on B6 background, 
      known to carry unique tumor-specific transplantation antigens. Tumor necrosis 
      factor-alpha (TNF-alpha) release assays concurred with the in vivo rejection 
      tests. The strongest response in the TNF-alpha release was always obtained with 
      the corresponding tumor, with very limited cross-reactivity against five other MC 
      tumors or two virally induced B6 lymphomas. The specific TNF-alpha release from 
      the anti-MC tumor CTL lines was mainly mediated by CD8+ cells. T-cell lines from 
      intact and CD4-/- mice gave a similarly specific pattern. In contrast, T-cell 
      lines derived from CD8-/- mice cross-reacted with several other MC-induced 
      tumors. Peptides eluted from MC sarcomas under mild acid conditions were 
      fractionated by reverse-phase high performance liquid chromatography and tested 
      for their ability to sensitize the processing- and presentation-defective mutant 
      RMA-S line. Only one high performance liquid chromatographic fraction from each 
      of the three different tumor-derived peptide eluates capacitated RMA-S to induce 
      TNF-alpha release and sensitized the cell to the cytotoxic effect of the 
      corresponding tumor-specific T-cell line. A different Kb-restricted peptide 
      fraction was active for each of the three MC sarcomas tested, indicating that 
      they all expressed individually distinct peptide epitopes.
FAU - Kono, K
AU  - Kono K
AD  - Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
FAU - Petersson, M
AU  - Petersson M
FAU - Ciupitu, A M
AU  - Ciupitu AM
FAU - Wen, T
AU  - Wen T
FAU - Klein, G
AU  - Klein G
FAU - Kiessling, R
AU  - Kiessling R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptide Fragments)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 56-49-5 (Methylcholanthrene)
SB  - IM
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cross Reactions
MH  - Dose-Response Relationship, Immunologic
MH  - Epitopes/immunology/pharmacology
MH  - Histocompatibility Antigens Class I/*metabolism/pharmacology
MH  - Humans
MH  - Methylcholanthrene
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Peptide Fragments/immunology
MH  - Sarcoma, Experimental/chemically induced/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/*metabolism
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1995 Dec 1;55(23):5648-55.